Michael Quigley
Overview
Explore the profile of Michael Quigley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
New J, Cham J, Smith L, Puglisi L, Huynh T, Kurian S, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38296596
Background: Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging. Methods: An observational cohort...
2.
Collins N, Al Abosy R, Miller B, Bi K, Zhao Q, Quigley M, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35264433
Background: Oncogenes act in a cell-intrinsic way to promote tumorigenesis. Whether oncogenes also have a cell-extrinsic effect on suppressing the immune response to cancer is less well understood. Methods: We...
3.
You D, Hillerman S, Locke G, Chaudhry C, Stromko C, Murtaza A, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33408094
Background: Hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) has been demonstrated as a negative intracellular immune checkpoint in mediating antitumor immunity in studies with HPK1 knockout and kinase dead mice....
4.
Nicholson L, McLawhon R, Kurian S, Fitzgerald R, Case J, Marsh C, et al.
Am J Infect Control
. 2021 Jan;
49(4):506-507.
PMID: 33388312
Coronavirus Disease 2019 infections among healthcare workers were widely reported in China and Europe as the pandemic expanded to the United States. In order to examine the infection rate among...
5.
Unsinger J, Walton A, Blood T, Tenney D, Quigley M, Drewry A, et al.
J Leukoc Biol
. 2020 Dec;
109(4):697-708.
PMID: 33264454
A defining feature of protracted sepsis is development of immunosuppression that is thought to be a major driving force in the morbidity and mortality associated with the syndrome. The immunosuppression...
6.
Davra V, Kumar S, Geng K, Calianese D, Mehta D, Gadiyar V, et al.
Cancer Res
. 2020 Nov;
81(3):698-712.
PMID: 33239426
Despite the promising clinical benefit of targeted and immune checkpoint blocking therapeutics, current strategies have limited success in breast cancer, indicating that additional inhibitory pathways are required to complement existing...
7.
Johnston R, Su L, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al.
Nature
. 2019 Oct;
574(7779):565-570.
PMID: 31645726
Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer. Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) partially reverse this...
8.
Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, et al.
Clin Cancer Res
. 2019 Oct;
25(22):6709-6720.
PMID: 31573956
Purpose: The success of checkpoint blockade has led to a significant increase in the development of a broad range of immunomodulatory molecules for the treatment of cancer, including agonists against...
9.
Caetano M, Younes A, Barsoumian H, Quigley M, Menon H, Gao C, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7576-7584.
PMID: 31540976
Purpose: Radiotherapy (RT) traditionally has been used for local tumor control in the treatment of cancer. The recent discovery that radiotherapy can have anticancer effects on the immune system has...
10.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, et al.
J Immunother Cancer
. 2019 Jul;
7(1):167.
PMID: 31272507
Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.